RU2018109902A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018109902A3 RU2018109902A3 RU2018109902A RU2018109902A RU2018109902A3 RU 2018109902 A3 RU2018109902 A3 RU 2018109902A3 RU 2018109902 A RU2018109902 A RU 2018109902A RU 2018109902 A RU2018109902 A RU 2018109902A RU 2018109902 A3 RU2018109902 A3 RU 2018109902A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237925P | 2015-10-06 | 2015-10-06 | |
| US62/237,925 | 2015-10-06 | ||
| PCT/IB2016/001526 WO2017060771A2 (en) | 2015-10-06 | 2016-10-06 | Combination therapies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018109902A RU2018109902A (ru) | 2019-11-07 |
| RU2018109902A3 true RU2018109902A3 (enExample) | 2020-03-05 |
| RU2727474C2 RU2727474C2 (ru) | 2020-07-21 |
Family
ID=58446480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018109902A RU2727474C2 (ru) | 2015-10-06 | 2016-10-06 | Виды комбинированной терапии для лечения рака |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9844540B2 (enExample) |
| EP (1) | EP3359255B1 (enExample) |
| JP (1) | JP6963545B2 (enExample) |
| KR (1) | KR20180058716A (enExample) |
| CN (1) | CN108136207A (enExample) |
| AU (1) | AU2016336133B2 (enExample) |
| BR (1) | BR112018003232A2 (enExample) |
| CA (1) | CA2997671A1 (enExample) |
| HK (1) | HK1259342A1 (enExample) |
| MX (1) | MX382754B (enExample) |
| RU (1) | RU2727474C2 (enExample) |
| WO (1) | WO2017060771A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| CA3060510A1 (en) | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
| US12006553B2 (en) | 2017-05-19 | 2024-06-11 | Lunella Biotech, Inc. | Companion diagnostics for mitochondrial inhibitors |
| JP6938682B2 (ja) | 2017-05-19 | 2021-09-22 | ルネラ・バイオテック・インコーポレーテッド | アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬 |
| CU20190106A7 (es) | 2017-06-26 | 2020-11-30 | Lunella Biotech Inc | Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas |
| EP4324460A3 (en) | 2017-09-15 | 2024-04-24 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| US20190134219A1 (en) * | 2017-09-15 | 2019-05-09 | Ampersand Biopharmaceuticals, Inc. | Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases |
| CA3126818A1 (en) * | 2019-01-16 | 2020-07-23 | Apogee Biotechnology Corporation | Combination of a sk2 inhibitor and an inhibitor of a checkpoint pathway, uses and pharmaceutical compositions therof |
| WO2020154716A1 (en) * | 2019-01-26 | 2020-07-30 | University Of Rochester | Compositions and methods for treating prostate cancer |
| US11052073B1 (en) | 2020-03-10 | 2021-07-06 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection |
| US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
| CN119700770A (zh) * | 2025-01-09 | 2025-03-28 | 首都医科大学附属北京佑安医院 | 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2189001A1 (en) | 1994-04-26 | 1995-11-02 | Nobuhiro Narita | Medicinal composition as a remedy for nonsmall cell lung cancer |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| BR9912327B1 (pt) * | 1998-07-20 | 2013-11-12 | Inibidores da uroquinase | |
| AUPR644301A0 (en) * | 2001-07-17 | 2001-08-09 | Unisearch Limited | Method and composition for treatment of cancer |
| US6864264B1 (en) * | 2002-08-20 | 2005-03-08 | Gloria L. Anderson | 1-adamantyl chalcones for the treatment of proliferative disorders |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| DE102004057195A1 (de) * | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
| US20060142304A1 (en) | 2004-12-27 | 2006-06-29 | Michael Southall | Method for treating or preventing pruritic and neurogenic skin disorders |
| US20060270631A1 (en) | 2005-05-26 | 2006-11-30 | Smith Charles D | Methods for the treatment and prevention of angiogenic diseases |
| MX2007015863A (es) * | 2005-06-17 | 2008-04-02 | Apogee Biotechnology Corp | Inhibidores de esfingosina cinasa. |
| TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
| US20080226624A1 (en) * | 2007-03-07 | 2008-09-18 | Wolfgang Schmalix | Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect |
| PL2247291T3 (pl) * | 2008-02-08 | 2019-05-31 | Red Hill Biopharma Ltd | Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| EP3560497A1 (en) * | 2012-08-30 | 2019-10-30 | The Texas A&M University System | Compositions and methods for drug-sensitization or inhibition of a cancer cell |
| SG11201703307WA (en) * | 2014-10-24 | 2017-05-30 | Redhill Biopharma Ltd | Therapy for inhibition of single-stranded rna virus replication |
-
2016
- 2016-10-06 CA CA2997671A patent/CA2997671A1/en not_active Abandoned
- 2016-10-06 WO PCT/IB2016/001526 patent/WO2017060771A2/en not_active Ceased
- 2016-10-06 JP JP2018517826A patent/JP6963545B2/ja active Active
- 2016-10-06 US US15/287,381 patent/US9844540B2/en active Active
- 2016-10-06 AU AU2016336133A patent/AU2016336133B2/en not_active Ceased
- 2016-10-06 MX MX2018004309A patent/MX382754B/es unknown
- 2016-10-06 RU RU2018109902A patent/RU2727474C2/ru active
- 2016-10-06 EP EP16853154.9A patent/EP3359255B1/en active Active
- 2016-10-06 HK HK19101708.0A patent/HK1259342A1/zh unknown
- 2016-10-06 CN CN201680058309.3A patent/CN108136207A/zh active Pending
- 2016-10-06 KR KR1020187007757A patent/KR20180058716A/ko not_active Ceased
- 2016-10-06 BR BR112018003232A patent/BR112018003232A2/pt not_active IP Right Cessation
-
2017
- 2017-11-07 US US15/805,682 patent/US10463654B2/en active Active
-
2019
- 2019-09-17 US US16/573,325 patent/US10946000B2/en active Active
-
2021
- 2021-01-12 US US17/147,093 patent/US11633385B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018533560A (ja) | 2018-11-15 |
| EP3359255B1 (en) | 2025-12-24 |
| US10946000B2 (en) | 2021-03-16 |
| US10463654B2 (en) | 2019-11-05 |
| EP3359255A4 (en) | 2019-06-12 |
| MX2018004309A (es) | 2018-05-22 |
| EP3359255A2 (en) | 2018-08-15 |
| RU2727474C2 (ru) | 2020-07-21 |
| US20200113881A1 (en) | 2020-04-16 |
| WO2017060771A2 (en) | 2017-04-13 |
| RU2018109902A (ru) | 2019-11-07 |
| US9844540B2 (en) | 2017-12-19 |
| AU2016336133A1 (en) | 2018-03-15 |
| BR112018003232A2 (pt) | 2018-09-25 |
| WO2017060771A3 (en) | 2017-07-06 |
| US11633385B2 (en) | 2023-04-25 |
| JP6963545B2 (ja) | 2021-11-10 |
| US20170095460A1 (en) | 2017-04-06 |
| US20210128538A1 (en) | 2021-05-06 |
| HK1259342A1 (zh) | 2019-11-29 |
| CA2997671A1 (en) | 2017-04-13 |
| CN108136207A (zh) | 2018-06-08 |
| AU2016336133B2 (en) | 2021-02-25 |
| MX382754B (es) | 2025-03-13 |
| US20180125831A1 (en) | 2018-05-10 |
| KR20180058716A (ko) | 2018-06-01 |